Tech Company Financing Transactions
InCarda Therapeutics Funding Round
On 4/29/2015, InCarda Therapeutics raised $5 million in Series A funding from Morningside Group and private investors.
Transaction Overview
Company Name
Announced On
4/29/2015
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series A
Investors
Morningside Group (Lead Investor) (Reenie McCarthy)
Proceeds Purpose
Proceeds from the financing will be used to further the company's lead cardiovascular program for an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
39899 Balentine Dr. 185
Newark, CA 94560
USA
Newark, CA 94560
USA
Phone
Undisclosed
Website
Email Address
Overview
Incarda Therapeutics develops treatments for cardiovascular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Grace Colón
Chief Financial Officer
Guy Anthony
Chief Medical Officer
Luiz Belardinelli
Chief Operating Officer
Carlos Schuler
Controller
Leo Santana
Vice President
Debra Echt
VP - Bus. Development
Jeffrey Ho
VP - Human Resources
Anna Popovici
VP - Operations
Meisa Propst
VP - Product Management
Mick Hurrey
VP - R & D
Prashanti Madhavapeddi
VP - Regulatory Affairs
Margaret Dillon
Browse more venture capital transactions:
Prev: 4/29/2015: DriveWealth venture capital transaction
Next: 4/29/2015: ShipBob venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs